Register for an account


Enter your name and email address below.

Your email address is used to log in and will not be shared or sold. Read our privacy policy.


Website access code

Enter your access code into the form field below.

If you are a Zinio, Nook, Kindle, Apple, or Google Play subscriber, you can enter your website access code to gain subscriber access. Your website access code is located in the upper right corner of the Table of Contents page of your digital edition.


Four Hemophiliac Patients Successfully Treated with Gene Therapy

80beatsBy Veronique GreenwoodDecember 13, 2011 3:53 AM


Sign up for our email newsletter for the latest science news



, a disease whose victims can suffer serious internal bleeding and may bleed to death from injuries, has a long and eventful history. Caused by defective blood clotting factors, the disease has been with us since at least the second century

, when a rabbi gave mothers whose first two sons had bled to death from circumcision wounds permission to leave the third sons uncircumcised. It also famously afflicted several members of European royal families

. But a study

published in the New England Journal of Medicine brings us a bit closer to a new kind of historic event: a cure. Following up on years of preclinical trials, including the curing of hemophiliac mice earlier this year

, scientists gave six patients a gene therapy

treatment, injecting them with a specially built virus carrying a functioning version of the gene for the defective clotting factor. The virus inserted the gene into liver cells, which proceeded to manufacture the clotting factor, and the patients maintained elevated levels of it for over 6 months. Four of the patients were able to stop receiving injections of clotting factor (the current treatment) altogether. The scientists are monitoring patients for any signs of liver cancer caused by the virus inserting the gene in an inopportune location, a known risk in gene therapy, but thus far, there have been no signs of such complications. The next stage, a trial of 20 patients, will assess what dosage of virus is necessary to get enough liver cells making clotting factor that most (hopefully all) patients can stop receiving injections. There are still plenty of ways that the treatment could fail before reaching the clinic. But here's hoping that the results continue to be this promising.

Image courtesy of Andrew Mason / flickr

2 Free Articles Left

Want it all? Get unlimited access when you subscribe.


Already a subscriber? Register or Log In

Want unlimited access?

Subscribe today and save 70%


Already a subscriber? Register or Log In